Phase 4 N=85 Negative Beta Glucan in ICU Patients
Candidemia
Primary: Evaluate the Ocurrence of Candidemia in Patients With Negative 1,3 Beta-D-glucan Who Discontinue Anidulafungin — 0; 21 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=63 A Study of Caspofungin Acetate (MK0991) for the Treatment of Esophageal Candidiasis or Invasive Candidiasis in Chinese Adults (MK-0991-066)
Fungal Infection
Primary: Number of Participants With One or More Drug-related Serious Adverse Events — 0 Participants
Phase 3 N=362 Fluconazole Prophylaxis for the Prevention of Candidiasis in Infants Less Than 750 Grams Birthweight
Candidiasis
Primary: Death or Candidiasis — 31; 37 participants
N/A N=117 Cortisol Response to Moderate and Deep Sedation in Children
Adrenal Insufficiency
Primary: Change From Baseline to Peak Salivary Cortisol Level — 2.9; 4.3; 3.3 Number (ratio of peak to baseline)
Phase 2 N=55 A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection)
Candidiasis, Vulvovaginal
Primary: Percentage of Subjects With Therapeutic Cure at 28 Days for All-Analysis Population — 9; 9; 11; 10 Participants
Phase 3 N=157 The Study Of Fluconazole For Vulvovaginal Candidiasis
Vulvovaginal Candidiasis
Primary: Therapeutic Outcome: Response Rate — 33.7; 54.2; 74.7 percentage of participants
N/A N=162 Invasive Candidiasis in Saudi ICUs
Invasive Candidiasis
Primary: Hospital Mortality — 95 Participants
N/A N=64 β-D-Glucan (BDG) Surveillance With Preemptive Anidulafungin vs. Standard Care for Invasive Candidiasis in Surgical Intensive Care Unit (SICU) Patients
Invasive Candidiasis
Primary: Clinical Utility of Biweekly β-D-glucan (BDG) Testing in At-risk Intensive Care Unit (ICU) Patients. — 3; 3; 19; 9 participants
Phase 2 N=107 CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension
Candidemia · Mycoses · Fungal Infection
Primary: Incidence of Treatment Emergent Adverse Events [Safety and Tolerability] — 71; 49; 55 Participants
Phase 2 N=22 Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis
Mycoses · Candidiasis, Invasive · Candidemia
Primary: Safety and Tolerability, Assessed by Adverse Events, Clinical Laboratory Results, Physical Examination Findings, ECG Results, and Vital Sign Measurements — 1; 1; 0; 0…
Phase 2 N=9 An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris
Candidemia · Invasive Candidiases · Candida Infection
Primary: Percentage of Participants With Treatment Success at End of Study Treatment (EOST) as Determined by Data Review Committee (DRC) — 88.9 Percentage of participants
Phase 4 N=282 Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis
Candidiasis
Primary: Number of Participants With Global Response of Success or Failure (Based on Clinical and Microbiological Response) at End of Treatment (EOT) — 170; 33 participants
Phase 3 N=70 Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive Candidiasis
Candidemia
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 17; 19; 30; 7 Participants
Phase 3 N=199 Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis
Candidemia · Mycoses · Fungal Infection
Primary: All-Cause Mortality (US FDA Only) — 19; 17; 3; 3 Participants
N/A N=30 Analysis of Snore Sound Following Minimal Invasive Surgery in Sleep-disordered Breathing Patients
Primary Snoring · Obstructive Sleep Apnea
Primary: Change in VAS Score After MIS — -1.4; -3.3 units on a scale — p=<0.05